PLX8394 was also shown to reduce ERK1/2 reporter activity and induce apoptosis ex vivo in BRAF-mutant melanoma xenografts with greater efficacy than vemurafenib; however, studies in vivo demonstrated acquired resistance through ERK1/2 reactivation but with different ERK-inhibitor sensitivity [68]. Here, MAPK3 is linked to melanoma.